Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Exclusivity Needed For Special Condition Switches – Expert

This article was originally published in The Pink Sheet Daily

Executive Summary

Without market exclusivity and a requirement to make generics also subject to consumer access restrictions, drug firms likely will not invest in novel switches, says a switch process veteran and Merck Consumer Care executive.

You may also be interested in...



FDA To Tackle Critical Generics Issue In Switch Paradigm Debate

Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.

FDA Digs Deeper On “New Paradigm” To Expand Rx Switches

The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.

Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access

FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel